What is the recommended dosage of scopolamine (anticholinergic) patches for motion sickness prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Dosage of Scopolamine Patches for Motion Sickness

For motion sickness prevention, apply one transdermal scopolamine patch (1 mg/3 days) to the hairless area behind one ear at least 4 hours before the antiemetic effect is required, for use up to 3 days. 1

Dosing Details and Administration

  • Each scopolamine transdermal system is formulated to deliver approximately 1 mg of scopolamine over 3 days 1
  • The patch contains a priming dose (140 μg) in the adhesive layer to accelerate achievement of steady-state blood levels, with the remainder released at a constant rate of approximately 5 μg/hour 2
  • Apply the patch to the hairless area behind one ear on clean, dry skin 1
  • For optimal effectiveness, apply the patch 6-8 hours before exposure to motion, as protective plasma concentrations (estimated at 50 pg/mL) are achieved after approximately 6 hours 2
  • Steady-state plasma concentration of about 100 pg/mL is achieved 8-12 hours after application 2
  • For faster protection, the patch may be applied 1 hour before the journey in combination with oral scopolamine (0.3 or 0.6 mg) 2

Duration and Replacement

  • If motion sickness prevention is needed for longer than 3 days, remove the first patch and apply a new one behind the other ear 1
  • After removal, fold the used patch in half with the sticky side together and discard properly to prevent accidental contact or ingestion 1
  • Wash hands thoroughly with soap and water after applying or removing the patch 1

Efficacy

  • Transdermal scopolamine has been shown to reduce the incidence and severity of motion sickness by 60-80% compared to placebo 2
  • It is more effective than oral meclizine or cinnarizine, and similar in efficacy to oral scopolamine 0.6 mg or promethazine plus ephedrine 2, 3
  • Studies at sea demonstrated that transdermal scopolamine provided protection against motion sickness at a significance level of p = 0.0001 compared to placebo 4

Important Precautions and Side Effects

  • Only wear one transdermal system at any time; using two patches does not improve efficacy but increases adverse effects 2
  • Common side effects include dry mouth (50-60% of users), drowsiness (up to 20%), and allergic contact dermatitis (10%) 2
  • Transient impairment of ocular accommodation may occur, particularly in hypermetropic individuals 5
  • Central nervous system effects may include reduced memory for new information, impaired attention, and lowered feelings of alertness 5
  • Scopolamine is contraindicated in patients with angle closure glaucoma 1
  • Neuropsychiatric adverse reactions may occur, including exacerbation of psychosis, agitation, speech disorder, hallucinations, paranoia, and delusions 1
  • Elderly patients may be more sensitive to the neurological and psychiatric effects 1

Clinical Pearls

  • Transdermal scopolamine is most effective against motion sickness 8-12 hours after application 2
  • Approximately 20-30% of subjects may fail to attain the estimated protective concentration, which may explain some treatment failures 2
  • The patch is particularly useful for long journeys (6-12 hours or longer) to avoid repeated oral doses 2
  • Avoid touching or applying pressure to the patch while it is being worn, as this may cause scopolamine to ooze out at the edge 1
  • Do not cut the transdermal system 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.